Celestoderm-V ointment

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

betamethasone (betamethasone 17-valerate)

Available from:

Schering-Plough Labo N.V.

ATC code:

D07AC01

INN (International Name):

betamethasone (betamethasone 17-valerate)

Dosage:

1mg/g

Pharmaceutical form:

ointment

Units in package:

aluminium tube 30g

Prescription type:

Prescription

Authorization status:

Registered

Authorization date:

2021-08-04

Summary of Product characteristics

[Organon] Proprietary
SUMMARY OF PRODUCT CHARACTERISTICS
[Organon] Proprietary
1.
NAME OF THE MEDICINAL
PRODUCT CELESTODERM-V
®
2.
COMPOSITION
1 g of ointment contains
_active substance:_ 1 mg betamethasone (as betamethasone 17-valerate
1.22 mg);
_excipients:_ paraffin white liquid, mineral oil.
3.
PHARMACEUTICAL FORM
Ointment.
_DESCRIPTION: _soft white homogenous ointment, without foreign
matters.
PHARMACOTHERAPEUTIC GROUP
Corticosteroids for dermatological use. Corticosteroids, potent (group
III).
АТС Code D07A C01.
4.1 THERAPEUTIC INDICATIONS
Relief of the inflammatory manifestations of corticosteroid-responsive
dermatoses such
as:
eczema
(atopic,
nummular),
contact
dermatitis,
seborrheic
dermatitis,
neurodermatitis, solar dermatitis, exfoliative dermatitis, dermatitis
due to radiation,
intertrigo, psoriasis (excluding disseminated psoriasis).
4.2. DOSAGE AND ADMINISTRATION
A thin film of Celestoderm-V
®
should be applied to the affected area 1-3 times daily
depending on severity of the condition. Application once or twice a
day is often
feasible and effective. Frequency of application should be determined
according to
severity of the condition. While mild cases may respond to once a day
application,
more severe cases may require more frequent application.
Do
not
apply
under
occlusive
dressings
as
it
can
potentiate
adverse
actions
of
medication.
Continuous use of the medication should not exceed 4 weeks. After
therapeutic effect
is achieved frequency of Celestoderm-V
®
should be decreased or less active topical
corticosteroid should be used,
and supportive therapy
should be
continued with
gradual withdrawal of the medication.
If clinical improvement is not achieved by two to four weeks,
examination should be
repeated, and treatment should be reviewed.
4.3 CONTRAINDICATIONS
Untreated skin diseases induced by bacterial infections of the skin
(e.g. pyogenic
[Organon] Proprietary
dermatitis, tuberculosis and syphilitic processes), viral infections
of the skin (e.g.
varicella, herpes simplex, herpes zoster, v